Skip to main content
SpringerLink
Log in

Nierenzellkarzinom

  • Chapter
  • First Online:
Facharztwissen Urologie

  • 5693 Accesses

Zusammenfassung

Unter den Nierenzellkarzinomen unterscheidet man das klarzellige, das papilläre und das chromophobe Nierenzellkarzinom. Weiterhin können in der Niere neuroendokrine Tumoren, das Duct-Bellini-Karzinom, Nierenzelladenome, papilläre, onkozytäre und metanephrogene Adenome auftreten. Bildgebend sichern die Sonografie und das CT (mit Kontrastmittel) bzw. das MRT die Diagnose, Biopsien erfolgen nur in Einzelfällen. Therapieoptionen sind radikale Nephrektomie oder Nierenteilresektion, sowohl offen chirurgisch als auch laparoskopisch. Bei kleinen Tumoren oder bei nicht operationsfähigen Patienten sind ablative Verfahren (Kryoablation, Radiofrequenzablation) eine Therapiealternative; Langzeitdaten hierfür fehlen jedoch. Im metastasierten Stadium sind die palliative bzw. zytoreduktive Nephrektomie und je nach Lokalisation und Ausmaß von Metastasen auch die Metastasenchirurgie therapeutische Optionen. In der systemischen Therapie der metastasierten Erkrankung werden überwiegend Thyrosinkinaseinhibitoren, mTor-Inhibitoren und VEGF-Antikörper (Target-Therapie) eingesetzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Atwell TD, Farrell MA, Leibovich BC (2008) Percutaneous renal cryoablation: experience treating 115 tumors. J Urol 179(6): 2136–40

    Article  PubMed  Google Scholar 

  • Bang HJ, Littrup PJ, Goodrich DJ et al. (2012) Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol 23(6): 770–7

    Article  PubMed  Google Scholar 

  • Bonsib SM, Gibson D, Mhoon M, Greene GF (2000) Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24: 451–458

    Article  CAS  PubMed  Google Scholar 

  • Cerfolio RJ, Allen MS, Deschamps C et al. (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57: 339–344

    Article  CAS  PubMed  Google Scholar 

  • Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1): CD001425

    Google Scholar 

  • Dechet CB, Zincke H, Sebo TJ et al. (2003) Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 169: 71–74

    Article  PubMed  Google Scholar 

  • Escudier B, Eisen T, Porta C et al.; ESMO Guidelines Working Group (2012) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii65–71

    Google Scholar 

  • Escudier B, Eisen T, Stadler WM et al.; the TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125–134

    Google Scholar 

  • Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2 b compared with interferon alfa-2 b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–1659

    Article  CAS  PubMed  Google Scholar 

  • Gleave ME, Elhilali M, Fradet Y et al. (1998) Interferon gamma-1 b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265–1271

    Article  CAS  PubMed  Google Scholar 

  • Hafez KS, Fergany AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162: 1930–1933

    Article  CAS  PubMed  Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271–2281

    Google Scholar 

  • Klingler HC (2007) Kidney cancer: energy ablation. Curr Opin Urol 17(5): 322–6, Review

    Google Scholar 

  • Kyllo RL, Tanagho YS, Kaouk JH et al. Prospective multi-center study of oncologic outcomes of robot-assisted partial nephrectomy for pT1 renal cell carcinoma. BMC Urol 30; 12: 11

    Google Scholar 

  • Larkin J, Paine A, Tumur I et al. (2013) Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 14(1): 27–39

    Article  CAS  PubMed  Google Scholar 

  • Ljungberg B, Cowan NC, Hanbury DC et al. (2010) European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3): 398–406

    Article  PubMed  Google Scholar 

  • Ljungberg B, Hanbury DC, Kuczyk MA, et al.; European Association of Urology Guideline Group for renal cell carcinoma (2009) Renal cell carcinoma guideline. http://www.uroweb.org/nc/professional-resources/guidelines/online

  • Maher ER, Webster AR, Moore AT (1995) Clinical features and molecular genetics of Von Hippel-Lindau disease. Ophthalmic Genet 16: 79–84

    Article  CAS  PubMed  Google Scholar 

  • Maher ER, Yates JR, Harries R, Benjamin C et al. (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77: 1151–11-63

    Article  CAS  PubMed  Google Scholar 

  • Matson MA, Cohen EP (1990) Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 69: 217–226

    Article  CAS  Google Scholar 

  • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–970

    Article  CAS  PubMed  Google Scholar 

  • Minor LD, Picken MM, Campbell SC et al. (2003) Benign renal tumors. AUA Update 22: 170–175

    Google Scholar 

  • Motzer RJ, Hutson T, Tomczak P et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115–124

    Article  CAS  PubMed  Google Scholar 

  • Patel N, Cranston D, Akhtar MZ et al. (2012) Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 110(9): 1270–5

    Article  PubMed  Google Scholar 

  • Pomer S, Klopp M, Steiner HH, Brkovic D, Staehler G, Cabillin-Engenhart R (1997) Brain metastases in renal cell carcinoma. Results of treatment and prognosis. Urologe (A) 36: 117–125

    Article  CAS  Google Scholar 

  • Retz M, Gschwend J (2009) Medikamentöse Tumortherapie in der Uroonkologie. Springer, Heidelberg

    Book  Google Scholar 

  • Riese W, Goldenberg K, Freytag A (1998) Spontanremissionen und deren Einfluß auf die Prognose von Patienten mit metastasiertem Nierenzellkarzinom. In: Heim M, Schwarz R, Hrsg. Spontanremissionen in der Onkologie. Schattauer, Stuttgart, S 223–240

    Google Scholar 

  • Rini BI, Halabi S, Rosenberg JE et al. (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol 26(33): 5422–8

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schlichter A, Wunderlich H, Junker K, Kosmehl H, Zermann DH, Schubert J (2000) Where are the limits of elective nephron-sparing surgery in renal cell carcinoma? Eur Urol 37: 517–520

    Article  CAS  PubMed  Google Scholar 

  • Sternberg CN, Hawkins RE, Wagstaff J et al. (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 49(6): 1287–96

    Article  CAS  PubMed  Google Scholar 

  • Tanagho YS, Figenshau RS, Bhayani SB (2013) Technique, outcomes, and evolving role of extirpative laparoscopic and robotic surgery for renal cell carcinoma. Surg Oncol Clin N Am 22(1): 91–109

    Article  PubMed  Google Scholar 

  • Volpe A, Panzarella T, Rendon RA et al. (2004) The natural history of incidentally detected small renal masses. Cancer 15: 738–745

    Article  Google Scholar 

  • Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (2006) Campbell Walsh Urology Edition. Elsevier Health Sciences

    Google Scholar 

  • Wittekind CH, Meyer HJ (20 10) TNM. Klassifikation maligner Tumoren. Wiley-Blackwell, Hoboken, USA

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Auguststr. 4, 23611, Bad Schwartau, Deutschland

    V. Rohde

Authors
  1. V. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Bundeswehrzentralkrankenhaus, Koblenz, Germany

    Hans-Ulrich Schmelz

  2. Klinik für Urologie, Bundeswehrkrankenhaus, Ulm, Germany

    Christoph Sparwasser

  3. Klinik u. Polikl. f. Urologie, Kinderurol. u Andrologie, Universitätsklinikum Gießen, Gießen, Germany

    Wolfgang Weidner

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rohde, V. (2014). Nierenzellkarzinom. In: Schmelz, HU., Sparwasser, C., Weidner, W. (eds) Facharztwissen Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-44942-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-44942-0_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-44941-3

  • Online ISBN: 978-3-642-44942-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation